← Back to Cibo Flash
Earnings

Immuneonco-B (01541) announced interim results

  • RevenueRMB25.4M
  • Net profitRMB-1.7bn
  • Profit attributable to ownersRMB-1.6bn
  • Revenue YoY-33.1%
  • Net profit YoY-8.4%
  • Depreciation & amortisationHK$14.6M
  • Capital expenditureHK$-1.3M
  • Interest-bearing debtHK$2.3bn

Source Immuneonco-B

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect